Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 3/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589720 | 0.86 | GSK3B (0.47) | AXLFGFR1FGFR2PDPK1JAK2 | |
| SCHEMBL16095565 | 0.82 | AXL (0.50) | AXLFGFR1FGFR2PDPK1JAK2 | |
| SCHEMBL13375265 | 0.80 | FGFR1 (0.44) | FGFR1FGFR2PDPK1JAK2GSK3B | |
| SCHEMBL6016609 | 0.79 | SMN1; SMN2 (0.53) | AXLGSK3BMAPTPKMCHEK1 | |
| SCHEMBL5953156 | 0.79 | MAP2K4 (0.51) | — | |
| SCHEMBL13726913 | 0.78 | AXL (0.47) | AXLFGFR1FGFR2PDPK1JAK2 | |
| SCHEMBL922069 | 0.77 | PDPK1 (0.65) | AXLFGFR1FGFR2PDPK1JAK2 | |
| SCHEMBL5952442 | 0.76 | DYRK1A (0.54) | GSK3BKDM4EMEN1MAPTKMT2A | |
| SCHEMBL445902 | 0.76 | FGFR1 (0.50) | AXLFGFR1FGFR2PDPK1JAK2 | |
| SCHEMBL15652838 | 0.75 | TTK (0.49) | FGFR1PDPK1GSK3BKDM4ECHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
| US-7312233-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312233-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312233-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1863757-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1853269-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007100758-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2006099410-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060205773-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-09-14 | — | — | US | disclosed |
| WO-2006093832-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | AXL 4133/4885FGFR1 997/4885FGFR2 1329/4885 |
| US-20060205773-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | AXL 4103/4885FGFR1 1056/4885FGFR2 1287/4885 |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | AXL 4103/4885FGFR1 1056/4885FGFR2 1287/4885 |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | DSTYK, ABL1, EEF2K | AXL 544/4885FGFR1 838/4885FGFR2 979/4885 |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | AXL 4103/4885FGFR1 1056/4885FGFR2 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.